Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Initiatives
-
The main aim of the study was to determine in screenees ages 55-74 at entry whether screening with flexible sigmoidoscopy (60-cm sigmoidoscope) can reduce mortality from colorectal cancer, whether screening with chest X-ray can reduce mortality from lung cancer, whether screening men with digital rectal examination (DRE) plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer, and whether screening women with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer.
Secondary objectives are to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive value; to assess incidence, stage, and survival of cancer cases; and to investigate biologic and/ or prognostic characterizations of tumor tissue and biochemical products as intermediate endpoints.
- Start Year
- 1993
- Funding
- National Cancer Institute (NCI)
- Supplementary Information
- https://cdas.cancer.gov/plco/
Visit PLCO
| Investigators | Contacts |
|---|---|
|
Design
- Study design
- Clinical trial
- Follow Up
- In the intervention arm, the PSA and CA125 tests are performed at entry, then annually for 5 years. The DRE, TVU, and chest X-ray exams are performed at entry and then annually for 3 years. Sigmoidoscopy is performed at entry and then at the 5-year point. Participants in the control arm follow their usual medical care practices. Participants will be followed for at least 13 years from randomization to ascertain all cancers of the prostate, lung, colorectum, and ovary, as well as deaths from all causes.
- Supplementary Information
- https://cdas.cancer.gov/datasets/plco/
Marker Paper
Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6 Suppl):251S-272S. doi:10.1016/s0197-2456(00)00097-0 Format:
PUBMED 11189683
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 155,000
- Number of participants with biosamples
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |
Availability of access information
On the study website : https://prevention.cancer.gov/major-programs/pr...